新聞中心
關注我們
14 May
2019

MSCI香港微型指數納入19隻股份 剔出8隻股份

<AASTOCKS>

MSCI宣布2019年5月股票市場指數半年度檢討結果,其中香港微型指數納入19隻股份,同時剔出8隻股份,所有變動將於5月28日收市後生效。

MSCI香港微型指數加入股份包括知臨集團(APTORUM GROUP)、亞證地產(00271.HK)、奧星生命科技(06118.HK) 、優品360(02360.HK)、人和科技(08140.HK)、中國中石控股(01191.HK)、中國通海金融(00952.HK)、德基科技(01301.HK)、廣駿集團(08516.HK)、長城環亞(00583.HK)、興銘控股(08425.HK)、港亞控股(01723.HK)、香港金融集團(00007.HK)、敘福樓集團(01978.HK)、仁智國際(08082.HK)、成志控股(01741.HK) 、新昌創展(01781.HK)、WAC HOLDINGS(08619.HK) 及信源企業(01748.HK) 。

相關內容《公司業績》匯友生命科學(08088.HK)首季虧損收窄至2,077萬元

該指數同時剔出匯友生命科學(08088.HK)、ECARGO HOLDINGS、威華達控股(00622.HK)、智傲控股(08282.HK)、榮豐聯合(03683.HK)、MEGA EXPO HOLDINGS(01360.HK)、美瑞健康國際(02327.HK)及惠記集團(00610.HK)。

(Source: http://www.aastocks.com/tc/stocks/news/aafn-content/now.941090/popular-news)

28 Apr
2019

香港製藥業初創企業與新加坡技術機構共同參與風險投資基金

<南華早報>
(新聞只有英文版本)

Aptorum Group, a Hong Kong drug developer listed on Nasdaq, will invest in health care start-ups in Singapore, working alongside the city state’s government technology agency to channel US$90 million into promising companies.

Aptorum and Aeneas Capital, both controlled by boutique investment bank co-founder Ian Huen Chung-yuen, signed an agreement with A*ccelerate Technologies on Wednesday to invest the funds over the next five years.

A*ccelerate operates under the Singapore’s Agency for Science, Technology and Research, and is tasked with helping to commercialise ideas and intellectual capital into marketable products and services.

The pact would allow Aptorum and Aeneas to leverage financial and technology development resources regionally and expand beyond Hong Kong when it comes to development of its own drug candidates.

“Hong Kong’s relatively small population means the number of patients for clinical trials is quite limited and trials need to be conducted elsewhere,” said Huen, Aptorum’s founder and chief executive. “Our collaboration with [the agency] ... will allow us to access and develop the excellent expertise and technological ecosystems in Singapore.”

Huen declined to divulge each party’s capital contribution toward the US$90 million, which will be deployed to support up to 20 start-ups.

Aptorum and the agency plan to cooperate in the application of solutions to enable more accurate 2D and 3D magnetic resonance imaging in the field of surgical robotics.

Aptorum, set up in 2017 through licensing agreements with units of the University of Hong Kong, Chinese University of Hong Kong and Hong Kong Polytechnic University, has obtained rights to further develop and commercialise various drugs.

These include drug candidates for influenza, MRSA – an antibiotics-resistant bacteria infection – and endometriosis, a painful disorder affecting women.

Huen said it expects to begin phase one clinical trials on three drug candidates between next year and 2021, each trial costing around US$5 million.

Having raised only US$12 million from its listing on Nasdaq in December, Huen said the company will need to raise additional funds over time.

The company employs around 80 staff, mainly in Hong Kong and operates a research facility at Science Park in Pak Shek Kok in the New Territories.

This article appeared in the South China Morning Post print edition as: HK drug firm looks to Singapore deals

(Sources: https://www.scmp.com/business/money/markets-investing/article/3007884/hong-kong-pharma-start-joins-singapore-technology)

26 Apr
2019

知臨集團成立子公司Smart Pharma 專注計算機輔助藥物再利用

<金融界>

  2019年4月24日/亞洲-新加坡,知臨集團(納斯達克股票代碼:APM)今日宣布成立子公司Smart Pharma(“SmartP”)。 SmartP主要運營創新的計算機輔助藥物再利用之發現、建模和驗證平台,相關平台統稱為“Smart-ACTTM”平台。

  Smart-ACTTM代表了治療藥物加速商業化,並在系統地從現有已獲批准的藥物分子中篩選可針對特定治療靶標的候選藥物方面擁有頂尖技術。具體而言,Smart-ACTTM平台由一系列模塊和流程組成,相關的模塊和流程可模擬藥物分子對疾病的有效性以實現結果預測和選擇。 Smart-ACTTM平台初期將專注於篩查孤兒病或未被滿足的醫療需求之疾病的藥物分子。

  截至目前,SmartP通過Smart-ACTTM平台已成功地完成對1,615種化合物靶向神經母細胞瘤(“NB”)預後不良相關的3種治療靶點蛋白的篩查。 NB是一種在某些類型的神經組織中形成的癌症,常見於腎上腺、脊柱、胸部、腹部以及頸部。 Smart-ACTTM平台的初步研究結果已鎖定了許多潛在的可再利用的候選藥物,這些候選藥物可能為治療該種疾病帶來希望。隨後,SmartP將通過與知臨集團的合作,進一步對該類候選藥物進行體外和體內實驗,以評估和驗證候選藥物對於該新適應症的可用性。

  藥物再利用通常是將已獲批准或正在開發的藥物用於與其最初開發目標不同的適應症。這些藥物分子的安全性和CMC特性通常是比較明確的,因此藥物再利用意味著一種低風險的藥物發現/開發方法。沙利度胺是眾所周知的一個藥物再利用成功案例,它最初用於治療孕吐,但由於其存在出生缺陷的副作用而被迫退出市場。其後通過藥物再利用開發,沙利度胺重新被用於治療多發性骨髓瘤。

  通過Smart-ACTTM平台,SmartP的目標是每年發現高達10個再利用候選藥物,該平台還將繼續開發及豐富其知識產權庫以促進此類發現。

  有關Smart-ACTTM平台的更多信息,請瀏覽我們的網站:http://www.smtph.com。

知臨集團與Smart Pharma的創始人禤駿遠先生表示:“我們的Smart-ACTTM平台是一種創新的工具,它完全改變了傳統上依賴於分散和偶然發現的藥物再利用和發現行業。相反,我們Smart-ACTTM平台是基於計算機程序對藥物分子進行系統性的篩查和預測,以加速治療藥物商業化進程。該平台初期專注研究孤兒疾病和未被滿足醫療需求的疾病。知臨集團對Smart Pharma取得的進展感到非常鼓舞,Smart Pharma將積極尋求與更廣泛的行業進行合作和共同開發的機會。”

  關於知臨集團

  知臨集團是一家致力於開發和商業化多種治療和診斷技術以解決未被滿足之醫療需求的製藥公司。當前,知臨集團正在進行神經內科、傳染病、胃腸病、癌症和其他疾病領域的治療和診斷項目,以及非治療領域如外科機器人(16.75 +0.78%,診股)項目,並於香港運營醫療診所——知仁醫療,該診所初期著重於治療現代久坐不動生活方式與人口老齡化所致的慢性病。

  有關知臨集團的更多信息,請瀏覽www.aptorumgroup.com。

  關於Smart Pharma

  Smart Pharma的控股公司SMTPH有限公司及其集團公司均為知臨集團全資子公司,專注於開發其Smart-ACTTM平台,以革新藥物的發現和開發。

  有關Smart Pharma的更多信息,請瀏覽www.smpth.com.

  免責聲明與前瞻性陳述

  本新聞稿包含有關知臨集團及其未來預期、計劃和前景的陳述,這些陳述構成了1995年“私人證券訴訟改革法案”界定的“前瞻性陳述”。為此目的,此處包含的任何非陳述歷史事實的陳述均可被視為前瞻性陳述。在某些情況下,您可以通過諸如“可以”、“應該”、“預期”、“計劃”、“預計”、“可能”、“打算”、“目標”、“項目”、“考慮”、 “相信”、“估計”、“預測”、“潛在”或“繼續”,或者這些術語及其他類似表達的否定形式來識別前瞻性陳述。知臨集團的這些前瞻性陳述主要基於其目前的預期及其對認為可能影響其業務、財務狀況和經營業績的未來事件和趨勢的預測。這些前瞻性陳述僅反映截止在本新聞稿發布之日的信息,並受若干風險、不確定性和假設的影響,包括但不限於與其宣布的管理和組織變更相關的風險、關鍵人員的持續服務和可用性、其通過為其他消費者細分市場提供額外產品而擴充產品線的能力、公司預期的增長戰略、業務中的預期趨勢和挑戰、其對供應鏈的期望及供應鏈的穩定性,以及知臨集團於2018年12月4日向美國證券交易委員會(“SEC”)提交的招股說明書(文件號333-227198)及未來知臨集團可能向SEC提交的其他文件中更加充分描述的風險。知臨集團不承擔因新信息、未來事件或其他原因而更新本新聞稿中包含的任何前瞻性陳述的義務。

(Source: http://stock.jrj.com.cn/hotstock/2019/04/25093127479607.shtml)

×
×
×
×
使用條款

This Website contains information concerning Aptorum Group Limited (“Aptorum Group”) and its affiliates that may be useful to Aptorum Group’s customers, suppliers, employees, directors and shareholders, as well as members of the general public. However, by using this Website you are accepting all of the terms of this disclaimer notice, including exclusions and limitations of liability. If you do not agree with anything in this notice, you should not use this Website.

Aptorum Group does not claim ownership of the materials and product images on the Website that are provided to us by our third party suppliers.

Where our Website contains links to other sites and resources provided by third parties, these links are provided for your information only. We have no control over the contents of those sites or resources, and accept no responsibility for them or for any loss or damage that may arise from your use of them. These links are provided solely as a convenience to you and not as an endorsement by us of the contents on such third party websites.

While reasonable efforts are made to ensure that the contents of this Website are accurate, this Website and its contents are provided on an “as is,” “as available” basis, without warranties of any kind, including any warranty that the Website will be kept up to date, be true and not misleading, or that the Website will always (or ever) be available for use. Aptorum Group and its affiliates disclaim all warranties, express or implied, with respect to the Website and its contents, including, without limitation, any warranties of accuracy, completeness, timeliness, non-infringement, title, merchantability, or fitness for a particular purpose. Because some jurisdictions do not permit the exclusion of certain warranties, these exclusions may not apply to you.

In no event will Aptorum Group or its affiliates be liable for any incidental, indirect, consequential, or special damages of any kind, or any damages whatsoever, including, without limitation, those resulting from loss of profits, contracts, goodwill, data, information, income, anticipated savings, or business relationships, whether or not Aptorum Group or its affiliates have been advised of the possibility of such damage, arising out of or in connection with the use of this Website or its contents or any other sites linked to this Website.

If you have any concerns about material which appears on our Website, please contact us. We have the right and the ability to remove immediately from our Website any material that is infringing, defamatory, offensive, abusive, harming, deceptive, threatening or otherwise illegal.